Say Hy to choice

HyQvia is the unique combination of IG + Hy offering multiple options for site of care* and dosing frequency¹

Based on the preferred site of care, you may want to consider different elements to start your patients on HyQvia.

HYQVIA CIDP dosing in-center option with HCP support.

HYQVIA CIDP dosing options: home self-infusion or with HCP/ caregiver support.

HCP=healthcare professional; Hy=hyaluronidase; IG=immune globulin; IVIG=intravenous immune globulin; SCIG=subcutaneous immune globulin.

*Patients can receive HyQvia treatment at an infusion center, in hospital, or at home. It can be given by an HCP, self-administered after appropriate training, or given by a trained caregiver. A choice of home administration must be a joint decision between HCP and patient; patients cannot make this decision themselves.¹

Calculating the right dose and schedule of maintenance therapy for your adult patients with CIDP

HyQvia gives you and your patients administration schedule and dosing options¹*

Dose and dosing frequency can be adjusted based on the individual patient’s clinical response¹
The typical dosing interval for HyQvia in the clinical trial was 4 weeks. For patients with IVIG dosing >4 weeks, the dosing schedule can be converted to 3 or 4 weeks while maintaining the same monthly equivalent IgG dose¹

*Patients can receive HyQvia treatment at an infusion center, in hospital or at home. It can be given by an HCP, self-administered after appropriate training or given by a trained caregiver. A choice of home administration must be a joint decision between HCP and patient; patients cannot make this decision themselves.
^†Variations in the dosing interval of up to ±7 days or monthly equivalent dose amount of up to ±20% between the patient’s IgG infusions are considered a stable dose.⁵

A ramp-up that could be right for them

Ramp-up period can take 4-9 weeks, depending on the dosing interval and tolerability¹
Depending on the treating physician’s discretion, in patients who tolerate the first two infusions well, subsequent infusions may be administered by gradually increasing doses and decreasing dose intervals, considering the volume and total infusion time.¹

Recommended IVIG to HyQvia infusion dose ramp-up schedule¹

Transitioning from IVIG: Ramp-up period up to 4-9 weeks depending on dosing interval and tolerability¹

The first HyQvia infusion can be administered 2 weeks after the last IVIG infusion
The typical dosing interval range in the clinical trial for HyQvia was 4 weeks in 88.7% of patients in ADVANCE-1¹

Varied product administration characteristics

HyQvia enables SC administration of a full dose up to once monthly,^‡ with an average infusion time of approximately 2 hours.^1,5

	HyQvia administration (after ramp-up)	GAMUNEX^®-C	PANZYGA^®	Privigen^®	Hizentra^®
Administration frequency	Up to once monthly (every 2, 3, or 4 weeks)¹	Every 3 weeks over 1 or 2 consecutive days⁶	Every 3 weeks over 2 consecutive days⁸	Every 3 weeks over 1 or 2 consecutive days¹⁰	Once weekly¹²
Venous access	No IV cannulation; subcutaneous administration¹	Delivered intravenously⁶	Delivered intravenously⁸	Delivered intravenously¹⁰	No IV cannulation; subcutaneous administration¹²
Injection site	1, 2 or 3 sites¹	1 site⁷	1 site⁹	1 site¹¹	Max. 8 infusion sites at least 2 inches apart¹²
Infusion rate	Max. 300 mL/hr/site (for patients ≥40 kg); max. 160 mL/hr/site (for patients <40 kg)	Max. 4.8 mL/kg/hour⁶	Max. 7.2 mL/kg/hour⁸	Max. 4.8 mL/kg/hour¹⁰	Max. 50 mL/hr/site¹²
Infusion volume	Max. 600 mL/site (2 sites); Max. 400 mL/site (3 sites)				Max. 140 mL per infusion session¹²
Infusion time	Median (range) 116.5 (65, 259) minutes	Average 2.7 hours per infusion	Average 1.6 or 2.3 hours per infusion⁸		Average 1 hour per infusion¹³
Administrator	Self-infusion, HCP or caregiver-supported^1†	HCP⁶	HCP⁸	HCP¹⁰	HCP or self-infusion¹²

Based on information from product labeling. No head-to-head studies have been conducted. No representation of comparative safety, efficacy, or FDA-approved indications should be made from these data.

*Every 2, 3, or 4 weeks.¹
^†Patients can receive HyQvia treatment at an infusion center, in hospital or at home. It can be given by an HCP, self-administered after appropriate training or given by a trained caregiver. A choice of home administration must be a joint decision between HCP and patient; patients cannot make this decision themselves.¹

Methods to prepare and infuse HyQvia

When selecting and preparing a pump for administering HyQvia, the following criteria should be taken into consideration:

The IG component of HyQvia must be administered using an infusion pump capable of infusing a patient’s dose up to every 4 weeks and at an infusion rate of up to 300 mL/h/site¹
The selected pump should be indicated for subcutaneous (SC) use¹
The pump must have the ability to titrate the flow rate up or down, as required, to improve tolerability, while part of a fully assembled administration system¹
To ensure maximum flow rates, use a subcutaneous needle set that is 24 gauge and labeled for high flow rates

Find out more here.¹

Infusing with a peristaltic pump video

Watch our step-by-step infusion video for healthcare professionals.

Download our Dosing & Administration Guide on how to infuse HyQvia with a peristaltic pump.

Watch our Instruction for HyQvia Infusion video for nurses:

00:00 Say Hy to Infusing with a Peristaltic Pump
05:05 Hy1: Get ready
06:32 Hy2: Prepare the Hy
09:56 Hy3: Prepare the IG
13:15 Hy4: Infuse
18:38 Hy5: Finish up

CIDP=chronic inflammatory demyelinating polyneuropathy; HCP=healthcare professional; Hy=hyaluronidase; IG=immune globulin; IVIG=intravenous immune globulin; SC=subcutaneous.

Review safety information

Review Important Safety Information, including contraindications and other specific warnings and precautions to consider when prescribing and monitoring patients treated with HyQvia.

See safety information

Get answers to your questions. Talk to a representative about HyQvia.

Contact a Rep

Explore the MOA of HyQvia

Starting Patients

IMPORTANT SAFETY INFORMATION including BOXED WARNING for Thrombosis

INDICATION

HYQVIA is indicated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults. HYQVIA is for subcutaneous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS

Thrombosis may occur with immune globulin (IG) products, including HYQVIA. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
For patients at risk of thrombosis, administer HYQVIA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration.
Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human IG
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG
Known systemic hypersensitivity to hyaluronidase including Recombinant Human Hyaluronidase of HYQVIA
Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)

Warnings and Precautions

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human IG. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Thrombosis: Has been reported to occur following treatment with IG products, including HYQVIA and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Immunogenicity of Recombinant Human Hyaluronidase (rHuPH20): Non-neutralizing antibodies to the Recombinant Human Hyaluronidase component can develop. The clinical significance of these antibodies or whether they interfere with fertilization in humans is unknown.

Aseptic Meningitis Syndrome: Has been reported with use of IG, including HYQVIA and may occur more frequently in females. The syndrome usually begins within several hours to two days following IG treatment.

Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: HYQVIA contains blood group antibodies which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with intravenous (IV) use of IG products, especially those containing sucrose. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and consider lower, more frequent dosing. If renal function deteriorates, consider discontinuation.

Spread of Localized Infection: Do not infuse HYQVIA into or around an infected area due to potential risk of spreading a localized infection.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema may occur with IV administered IG. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because HYQVIA is made from human plasma, it may carry a risk of transmitting infectious agents (e.g. viruses, other pathogens). No cases of transmission of viral diseases or variant Creutzfeldt-Jakob disease (vCJD) have been associated with HYQVIA.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

Adverse Reactions

The most common adverse reactions observed in clinical trials in >5% of patients were: local reactions, headache, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and pain in extremity.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Use In Specific Populations

Pregnancy: Limited human data are available on the use of HYQVIA during pregnancy. The effects of antibodies to the Recombinant Human Hyaluronidase on the human embryo or fetal development are unknown. It is not known whether HYQVIA can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. HYQVIA should be given to a pregnant woman only if clearly needed.

Please click for Full Prescribing Information.